Fig 4.

H₂O₂-LCMV-vaccinated mice maintain stable CD8⁺ T cell immunodominance patterns following subsequent infection or booster vaccination. C57BL/6 mice underwent primary infection with 2 × 10⁵ PFU LCMV Arm or vaccination with H₂O₂-LCMV and 28 days later received a secondary live LCMV challenge or booster H₂O₂-LCMV vaccination. Combinations included LCMV Arm infection followed by LCMV Arm challenge (A and D), H₂O₂-LCMV vaccination followed by H₂O₂-LCMV boost (B and E), and H₂O₂-LCMV vaccination followed by LCMV Arm challenge (C and F). Immunodominance profiles were determined by stimulating T cells with a panel of 20 LCMV peptides followed by IFN-γ ICCS at day 5 (A to C) or day 42 (D to F) postchallenge or after booster vaccination. The data represent the averages ± SDs of 3 or 4 mice per group from 2 independent experiments.